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Abstract
Background: There is a substantial body of evidence on the efficacy of yoga in the management
of bronchial asthma. Many studies have reported, as the effects of yoga on bronchial asthma,
significant improvements in pulmonary functions, quality of life and reduction in airway hyper-
reactivity, frequency of attacks and medication use. In addition, a few studies have attempted to
understand the effects of yoga on exercise-induced bronchoconstriction (EIB) or exercise
tolerance capacity. However, none of these studies has investigated any immunological mechanisms
by which yoga improves these variables in bronchial asthma.
Methods: The present randomized controlled trial (RCT) was conducted on 57 adult subjects
with mild or moderate bronchial asthma who were allocated randomly to either the yoga
(intervention) group (n = 29) or the wait-listed control group (n = 28). The control group received
only conventional care and the yoga group received an intervention based on yoga, in addition to
the conventional care. The intervention consisted of 2-wk supervised training in lifestyle
modification and stress management based on yoga followed by closely monitored continuation of
the practices at home for 6-wk. The outcome measures were assessed in both the groups at 0 wk
(baseline), 2, 4 and 8 wk by using Generalized Linear Model (GLM) repeated measures followed by
post-hoc analysis.
Results:  In the yoga group, there was a steady and progressive improvement in pulmonary
function, the change being statistically significant in case of the first second of forced expiratory
volume (FEV1) at 8 wk, and peak expiratory flow rate (PEFR) at 2, 4 and 8 wk as compared to the
corresponding baseline values. There was a significant reduction in EIB in the yoga group. However,
there was no corresponding reduction in the urinary prostaglandin D2  metabolite (11β
prostaglandin F2α) levels in response to the exercise challenge. There was also no significant
change in serum eosinophilic cationic protein levels during the 8-wk study period in either group.
There was a significant improvement in Asthma Quality of Life (AQOL) scores in both groups over
the 8-wk study period. But the improvement was achieved earlier and was more complete in the
yoga group. The number-needed-to-treat worked out to be 1.82 for the total AQOL score. An
improvement in total AQOL score was greater than the minimal important difference and the same
outcome was achieved for the sub-domains of the AQOL. The frequency of rescue medication use
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showed a significant decrease over the study period in both the groups. However, the decrease
was achieved relatively earlier and was more marked in the yoga group than in the control group.
Conclusion: The present RCT has demonstrated that adding the mind-body approach of yoga to
the predominantly physical approach of conventional care results in measurable improvement in
subjective as well as objective outcomes in bronchial asthma. The trial supports the efficacy of yoga
in the management of bronchial asthma. However, the preliminary efforts made towards working
out the mechanism of action of the intervention have not thrown much light on how yoga works
in bronchial asthma.
Trial registration: Current Controlled Trials ISRCTN00815962
Background
Although the efficacy of yoga in treating bronchial
asthma[1] has been investigated since at least the 1960s
[2-9], most of the previous studies have been uncon-
trolled, and have evaluated only a few selected yogic pos-
tures or breathing exercises. To the best of our knowledge,
there is only one randomized controlled trial which has
evaluated the efficacy of an integrated package consisting
of yogic postures, breathing exercises, cleansing tech-
niques, meditation, devotional sessions and lectures[10].
However, even this study did not investigate the mecha-
nisms by which yoga improves the symptoms of bron-
chial asthma. The present randomized controlled trial was
undertaken to study the efficacy of a comprehensive life-
style modification and stress management program based
on yoga in subjects having mild or moderate bronchial
asthma. An attempt has also been made to monitor some
immunological indicators of severity of disease and mast
cell activation.
Methods
Subjects
The subjects were adult patients having mild or moderate
bronchial asthma who were either referred to the Integral
Health Clinic (IHC) of the All India Institute of Medical
Sciences (AIIMS) by AIIMS physicians or came to IHC in
response to our advertisements in local dailies.
The potential subjects went through a step-wise screening
procedure. The inclusion criteria consisted of (1) age 18
years or older; (2) an established diagnosis of mild-to-
moderate asthma for at least 6 months (meeting the
American Thoracic Society[11] spirometry criteria for
mild-to-moderate asthma, which requires either a forced
expiratory volume in 1 second [FEV1]/forced vital capacity
[FVC] below the lower limit of normal with a significant
response to a bronchodilator [a ≥12% increase and a ≥200
mL absolute increase in FEV1 15 minutes after the admin-
istration of 2 puffs of a short acting β-agonist] or peak
expiratory flow rate [PEFR] variability >20%); (3) taking
at least one of the following: inhaled β-agonists, methylx-
anthines, anticholinergics, inhaled corticosteroids; and
(4) stable medication dosing for the past month. Subjects
were excluded if they (1) smoked currently (or in the past
year) or had a smoking history of greater than 5 pack-
years; (2) had a concomitant lung disease; (3) were taking
leukotriene inhibitors or receptor antagonists, or mast
cell-stabilizing agents for at least 6 months; (4) practiced
yoga or any other similar discipline during 6 months pre-
ceding the study; (5) were pregnant; (6) had a chronic
medical condition that required treatment with oral or
systemic corticosteroids in the past month; (7) had a med-
ical condition that contraindicated exercise; or (8) had an
unstable medical condition.
Of the 138 potential subjects screened, 66 did not meet
the above-described eligibility criteria. Of the 72 eligible
subjects, only 60 were included in the study at the end of
the 1-week run-in period and the other 12 subjects were
self-withdrawn before randomization. The subjects com-
pleted the baseline measurements of all the outcome
parameters after randomization. These 60 subjects were
randomly allocated to either the yoga (intervention)
group (n = 30) or the wait-listed control group (n = 30).
However, one subject in the yoga group, and two subjects
in the control group discontinued midway in the study.
The results presented in this report are based on the data
collected from only the 57 subjects who completed the
study (yoga group, n = 29; control group, n = 28).
Experimental Design
The present study is an open-label randomized controlled
trial (RCT) with two parallel groups. The control group
received conventional care whereas the experimental
group received, in addition to conventional care, an inter-
vention based on yoga. The subjects from both groups
were on bronchodilators in the form of inhalers or
inhaled corticosteroids depending on the judgment of the
treating physician. None of the subjects was on systemic
or oral corticosteroid therapy. However, subjects were not
allowed to change their inhaled corticosteroid dose dur-
ing the study period. During the study, the control groupBMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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was offered a session on health education relevant to their
illness, and at the end of the 8-wk study period, the inter-
vention based on yoga. The outcome measures were
assessed in both groups at 0 wk (baseline), 2, 4 and 8 wk.
The subjects in neither group were encouraged to either
delay or reduce their rescue medication use, but were
instead advised to consult their treating physician for any
dose changes, if required.
Treatment Intervention
Participants assigned to the yoga group underwent a com-
prehensive yoga-based lifestyle modification and stress
management program for 4 hours a day for 2 weeks. The
sessions were conducted from 8 am to 12 noon. The sub-
jects were neither unemployed nor disabled. Their ability
to spend that much time in the clinic might be due to 'cul-
tural differences'. In India, the patient respects his thera-
pist and is willing to do whatever it takes to comply with
the prescribed treatment. Corresponding to this attitude,
the employer is also willing to bend the requirements of
the job to make it possible for the employee to get the
treatment. If the patient is a homemaker, other members
of the extended family are willing to pitch in with child-
care and other essential tasks to enable the patient to get
the treatment. The program consisted of lectures and prac-
tical sessions on asanas (postures), pranayamas (breath-
ing techniques), kriyas (cleansing techniques),
meditation and shavasana (a relaxation technique). The
4-hour sessions included asanas and pranayamas for 1
hour; breakfast and building up of group support for 30
min; lecture and discussion for 2 hours and meditation
for 30 min. The yoga practice sessions were conducted by
a qualified yoga instructor. The lectures were on yoga, its
place in daily life, its application to stress management,
fundamentals of nutrition and health education relevant
to their illness. Each subject received at least one session
of about one hour of individualized counseling. During
these individualized counselling sessions, the subject's
questions regarding yogic practices, diet, prognosis, test
results etc. were answered. In addition, family and social
histories of the subjects were taken to establish a good
rapport, and to discover any major mental stress, real or
perceived, which might be aggravating the disease. In case
of mental stress, some counselling, primarily in the form
of cognitive restructuring based on the spiritual philoso-
phy underlying yoga, was attempted. The counselling was
done by physicians with special interest in yoga and
mind-body medicine.
The physical practices consisted of elementary breathing
exercises and loosening exercises followed by asanas
under four categories (standing, sitting, prone and
supine), pranayama, kriyas, and meditation based on raja
yoga. Participants were instructed to follow a specific
breathing pattern during each asana and asked to hold
each pose in final position for up to 30 sec without hold-
ing their breath. Soothing instrumental music was played
while the participants were practicing the yoga techniques
to induce relaxation. Participants practiced yogic postures
with awareness focused on their physical movements and
breath. Each posture was followed by an appropriate
relaxation technique for a short period. The classes con-
cluded with deep relaxation in shavasana for about 15
min followed by guided imagery for about 5 min. The
yoga practice sessions were about one and a half hour dur-
ing the 2-wk training period and additional 6-wk home
practice. The level of compliance for yoga practice was
assured at least 5 days a week. The content of the daily
home practice sessions was the same as during the 2-wk
training, i.e. one hour of asanas and pranayama, 10 min
of relaxation and 20 min of meditation. Subjects were
provided printed material and audiocassettes to supple-
ment live instruction. The yoga group subjects' compli-
ance during the follow-up period was monitored by a
diary on their adherence to yoga practice, dietary advice
and rescue medication use, which they filled in everyday
and brought during each visit. An individual yoga practice
session was offered to the subjects during study evaluation
visits. The control group was also asked to keep a diary of
medication use and was attended by their treating physi-
cians during study evaluation visits. During the follow-up
period, telephonic support was also provided for motivat-
ing participants to improve their compliance.
The diet recommended for the yoga group was predomi-
nantly vegetarian; it mainly consisted of a combination of
cereals and pulses, preferably unrefined; moderate
amounts of judiciously chosen fat; moderate amounts of
milk and milk products; moderate amounts of spices; veg-
etables and fruits about 500 g, vegetables being predomi-
nantly of the leafy green variety, and at least some eaten
raw (uncooked).
Outcome measures and techniques of measurement
The outcome measures were spirometric indices of pul-
monary function, eosinophilic cationic protein as a
marker of the course of the disease[12]; the degree of exer-
cise-induced bronchoconstriction, urinary concentration
of the prostaglandin D2 metabolite, 11β prostaglandin
F2α before and after the exercise challenge as a marker of
mast cell activation, quality of life and frequency of rescue
medication.
Spirometric indices of pulmonary function
The indices of interest, viz. forced vital capacity (FVC),
forced expiratory volume in the first second of expiration
(FEV1), the ratio FEV1/FVC, peak expiratory flow rate
(PEFR) and average forced expiratory flow rate during the
expulsion of 25–75% of FVC (FEF25–75%) were measured
by computerized spirometric equipment (K4b2, COS-BMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
Page 4 of 12
(page number not for citation purposes)
MED srl, Italy). The FVC manoeuvre was repeated at least
thrice during each measurement. The highest of three
acceptable readings of FVC and FEV1 were taken as the val-
ues for that sitting.
Eosinophilic cationic protein (ECP)
The serum concentration of ECP was assessed by sand-
wich ELISA kit (MBL ECP ELISA kit, Japan, code No. 7618
E). The coefficients of variation for inter-assay and intra-
assay measurements were 10.7% and 11.1% respectively.
Exercise-induced bronchoconstriction (EIB)
The exercise challenge was given using a stationary bicycle
ergometer (Bodyguard®  990, Sandnes, Norway). The
workload was fixed at 80–85% of the maximum predicted
heart rate while pedalling at 60 revolutions per min. The
subjects were told to go on till they reach the limit of their
dyspnoea or inability to continue the exercise for any rea-
son. The duration of the exercise in different subjects
ranged from 3–7 min. The heart rate was monitored con-
tinuously through a remote sensor attached to the sub-
ject's chest (Polar Electro Inc., Finland) and displayed on
a computer screen. The exercise was performed in an air-
conditioned room with ambient temperature between 24
and 27°C, and relative humidity between 40 and 50%.
Thus the environmental conditions under which exercise
was performed at different sittings were comparable. The
degree of EIB was measured as highest degree of exercise-
induced change in FEV1 from 0 min (baseline) to 3, 8, 15
and 30 min post exercise.
Urinary 11β prostaglandin F2α (11β-PGF2α)
Urine was collected 5 min before exercise and again 30
min after the end of exercise. Urine samples were stored,
without the addition of any preservatives, at -20°C until
analysis. The concentration of 11β-PGF2α excretion was
estimated by using Enzyme Immuno Assay (EIA, Cayman
Chemical, Ann Arbor, MI, USA; Catalog No. 516521). The
inter-assay and intra-assay variations for 11β-PGF2α assay
were 9.7% and 5.5% respectively. To correct for the effect
of diuresis, creatinine concentrations were measured for
all urine samples by a commercially available colorimetric
assay (Wipro Biomed, Bangalore, India), using Jaffe' Rate
method[13]. Therefore, the urinary 11β prostaglandin
F2α concentrations were expressed as picogram per milli-
gram of creatinine[14].
Quality of Life
Quality of life was measured by using a self-administered
Asthma Quality of Life Questionnaire (AQOL) which is
available in bilingual form, i.e. English and Hindi[15].
The AQOL is a 32-item disease specific questionnaire that
has been validated to measure the problems that adult
patients with asthma experience in their daily lives[16]
and has also been validated on Indian population[17].
Subjects responded to each question on a 7-point scale (1
being maximum impairment; 7 being no impairment).
The overall quality of life score is the mean score of all the
32 items. Thus the score may vary from 1–7. The 32 items
are further grouped into four sub-domains viz., symp-
toms, activity limitation, emotional function and reactiv-
ity to environmental stimuli. The score for each sub-
domain was also calculated as the mean score for items
pertaining to that sub-domain. Thus, the score for each
sub-domain may also vary from 1–7.
Rescue medication
The subjects were asked at the beginning of the study to
add up how many times they had used a bronchodilator
inhaler during the preceding 2-wk as prescribed by the
physicians. For quantifying subsequent use, the subjects
were told to make a note in their diaries every time they
had to use rescue medication for getting quick relief from
symptoms such as wheezing, cough or shortness of
breath. At any point in time, the frequency of rescue med-
ication was calculated as the average number of times that
the medication had to be used in a day during the preced-
ing 2-wk.
Analysis of data
The baseline (0 wk) values of each outcome measure were
compared with the values obtained at 2, 4 and 8 wk by
Generalized Linear Model (GLM) repeated measures fol-
lowed by post-hoc analysis[18]. Categorical variables
were analyzed using Chi-square analysis. Continuous var-
iables were analyzed using Mann-Whitney U test, Fried-
man test for overall group significance or the independent
sample t-test, depending on the distribution of data. In
case of outcome variables which changed in the same
direction in both the interventional and control groups,
between-group comparisons were also made to determine
if the change in one group was significantly greater than
that of the other group.
The degree of EIB was quantified by the percentage of
highest fall in FEV1 reached after exercise during post-exer-
cise measurements (3, 8, 15 and 30 min) as compared to
the pre-exercise value. There was very high inter-individ-
ual variability in degree of EIB. Therefore the subjects were
divided into exercise-sensitive (ES) and exercise-resistant
(ER). Those who had a reduction of 15% or more in FEV1
post exercise at 0-wk were considered ES, and the rest ER.
The ECP values were log-transformed prior to analysis due
to their wide range. Urinary 11β-PGF2α concentrationsBMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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were not normally distributed and therefore expressed in
median and inter-quartile ranges. The percentage change
in urinary 11β-PGF2α following exercise was used for sta-
tistical analysis.
A change of ≥0.5 in the AQOL score has been considered
the Minimal Important Difference (MID) as clinically
meaningful difference[19]. Based on the MID, number
needed to treat (NNT) was calculated using the method
described by Gyuatt et al., (1998)[20] for trials with a par-
allel group design.
Differences were considered significant if p < 0.05. All sta-
tistical calculations were performed using the SPSS soft-
ware 10.0.1 release for Windows (SPSS Inc, Chicago IL,
USA).
Ethical considerations
The protocol of the study was approved by the Ethics
Committee of All India Institute of Medical Sciences. The
subjects signed an informed consent form before being
enrolled for the study and knew that they were free to
withdraw from the study at any stage without assigning
any reason.
Results
The demographics and baseline values of outcome varia-
bles of subjects are given in Tables 1 and 2. As seen in
these tables, the two groups are comparable at baseline in
every respect except PEFR expressed as percentage of the
predicted value.
The values of the outcome measures at different time
points during the study are given in Tables 3, 4, 5 and 6
and Figures 1, 2 and 3.
There were no significant changes in pulmonary function
indices in the control group during the course of the
study. In contrast, there was a steady and progressive
improvement in the subjects of yoga group during the
same period. The change in the yoga group was statisti-
cally significant for FEV1 at 8 wk and PEFR at 2, 4 and 8
wk, as compared to the corresponding baseline values
(Table 3). In addition, significant group mean differences
were observed between yoga and control groups over the
8-wk study period in PEFR, FEV1, FEV1/FVC and FEF25–
75%. In PEFR, since there is a significant baseline differ-
ence, baseline was considered as a constant covariate for
between-group comparisons.
There was no significant change in serum ECP levels dur-
ing the 8-wk study period in either group (Figures 1 and
2). The EIB decreased significantly in the yoga group, but
not in the control group over the 8-wk study period (Table
4). Subgroup analysis in ES subjects revealed significant
reduction in EIB over the 8-wk study period in both yoga
and control groups but the amount of reduction observed
was more marked in the yoga group than in the control
group. In ER subjects the change in EIB was not significant
in either group. Similar analysis of percentage change in
urinary 11β-PGF2α levels in response to the exercise chal-
lenge revealed no significant change during the study in
either group (Table 5). One interesting observation at 4-
wk in the control group (in ES subjects) was that the EIB
was rather significantly high, and this was associated with
a significant increase in urinary 11β-PGF2α excretion in
response to the exercise challenge as compared to the ES
subjects in yoga group (Tables 4 and 5).
The AQOL scores showed an improvement over the 8-wk
study period in both groups (Table 6). But the improve-
ment was achieved relatively earlier and was more com-
plete in the yoga group. At 2 wk, the improvement was
statistically significant as compared to the baseline score
in the total quality of life as well as each of the four sub-
domains in the yoga group, but not in the control group.
Even by 8-wk, significant improvement was seen in the
control group only in total AQOL and symptoms but not
in activity limitation, emotional function or the response
to environmental stimuli. The NNT was found to be 1.82
for the total score, 2.41 for symptoms score, 1.66 for activ-
ity limitation score, 1.91 for emotional function score and
1.70 for the response to environmental stimuli score,
which means ≤2 subjects needed to be treated with yoga
plus conventional treatment for one subject to have a clin-
ically meaningful improvement in quality of life over and
above the improvement that the subject would have expe-
rienced with conventional treatment alone.
The frequency of rescue meditation use showed a signifi-
cant decrease over the 8-wk study period in both the
groups. But the decrease in rescue meditation use was
achieved relatively earlier and was more marked in the
yoga group than in the control group (Figure 3). Rescue
medication use between yoga and control groups was sig-
nificantly different at 2 and 4 wk because of the remarka-
ble decrease in the frequency of the medication use only
in the yoga group.
Although the level of compliance for yoga practice aimed
at was at least 5 days a week, this level could not be sus-
tained throughout the 8 weeks of the study. The compli-
ance for yoga practice as reported by the subject was
(average number of practice days per week): Wk 0, 4.6 ±
0.5; Wk 2, 4.6 ± 1.1; Wk 4, 4.5 ± 1.2; and Wk 8, 4.4 ± 1.1.
Discussion
The present study has demonstrated that adding the mind
body approach of yoga to the predominantly physical
approach of conventional care results in measurableBMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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Table 1: Demographics and Baseline Values of Outcome Variables
Yoga group
(n = 29)
Control group
(n = 28)
p-value
Age, years (mean ± SD) 33.5 ± 11.4 33.4 ± 11.5 0.96
Males, n (%) 13 (45) 20 (71) 0.29
Females, n (%) 16 (55) 8 (29) 0.19
Weight, kg (mean ± SD) 61.3 ± 11.5 58.9 ± 9.7 0.93
Height, cm (mean ± SD) 162 ± 10.1 161.8 ± 7.4 0.40
Body Mass Index (BMI) (mean ± SD) 23.4 ± 4.3 22.6 ± 4.0 0.44
Family history of asthma present, n (%) 13 (44.8) 11 (39.3) 0.67
Duration of Asthma, years (mean ± SD) 11.6 ± 9.5 10.5 ± 11.9 0.22
Mild asthma, n (%) 13 (44.8) 11 (39.3) 0.78
Moderate asthma, n (%) 16 (55) 17 (60.7) 0.82
FVC (% of predicted) 78.7 ± 13.3 75.2 ± 15.0 0.35
FEV1 (% of predicted) 70.2 ± 17.4 62.5 ± 19.2 0.11
FEV1/FVC (% of predicted) 80.4 ± 11.5 73.7 ± 14.8 0.06
PEFR (% of predicted) 68.6 ± 18.4 57.4 ± 19.7 0.03
FEF25-75 (% of predicted) 38.4 ± 14.5 33.9 ± 18.3 0.31
Serum ECP level (ng/mL) 1.32 ± 0.51 1.25 ± 0.43 0.89
EIB (%fall in FEV1 with EC) 15.0 ± 14.0 9.1 ± 10.8 0.16
Urinary 11β-PGF2α before exercise (pg/mg of creatinine), median (IQR) 455.4
(107.2–1098.1)
223.7
(98.8–562.7)
0.12
Δ Urinary 11β-PGF2α (pg/mg of creatinine) with exercise challenge, median (IQR) 26.9 (7.4–218) 38.4 (3.1–108) 0.55
AQOL total score 3.72 ± 1.17 3.64 ± 1.14 0.80
AQOL symptoms score 3.77 ± 1.34 3.62 ± 1.42 0.70
AQOL activity limitation score 3.66 ± 1.13 3.67 ± 1.17 0.95
AQOL emotional function score 3.94 ± 1.47 3.59 ± 1.39 0.35
AQOL environmental stimuli score 3.72 ± 1.17 4.04 ± 1.42 0.14
Abbreviations: AQOL, Asthma Quality of Life; FEV1, forced expiratory volume in 1 second; FEF25–75%, forced mid-expiratory flow between 25% and 
75% of FVC; FVC, forced vital capacity; PEFR, peak expiratory flow rate; ECP, eosinophilic cationic protein; IQR, inter- quartile range; EC, exercise 
challenge; EIB, exercise-induced bronchoconstriction; 11β-PGF2α, 11β prostaglandin F2α.
p-value obtained by from Chi-square analysis or 't' test or Mann-Whitney U test depending on the type of variables.
All values are expressed as mean ± SD, except ECP expressed as log-transformed values and 11β-PGF2α as median with inter-quartile range.BMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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improvement in some subjective as well as objective out-
comes in bronchial asthma. There have been previous
RCTs on the efficacy of yoga which have arrived at similar
conclusions[3,6,10]. But none of the previous trials have
gone into the plausible mechanisms by which yoga might
help bronchial asthma even in a small way as the present
study has done. Since the major built-in difference
between the two groups was the yogic intervention during
8-wk of the study, any difference in the outcome is likely
to be due to yoga. The control being a wait-listed group, it
does not control completely for non-specific effects of the
experimental intervention such as expectation, belief, sub-
ject investment in time and effort, change in the subjects'
daily routine, investigator interaction, social interaction
and support, and placebo effect.
The 8-wk duration of the yogic intervention was an arbi-
trary compromise. It is long enough to demonstrate the
effect, but the ideal would be a much longer study. How-
ever, in practice the decline in compliance increases
steeply as the study gets longer, possibly owing to the time
commitment required from the subjects[9]. Since there is
no appropriate placebo possible for yoga, the subject can-
not be blinded. The allocation of the subjects to the two
groups was randomized, but the selection of subjects from
the patient population was not random. Every subject
who made it to our clinic to volunteer for the trial was
already convinced in his mind about the beneficial effects
of yoga because of its popularity in India. This is an inher-
ent flaw of such trials, and limits the extrapolation of
results to the entire subject population. However, this lim-
Table 2: Daily dose of inhaled corticosteroids and rescue medication at baseline
Type of medication Yoga
(No. of subjects)
Control
(No. of subjects)
p-value
Mean inhaled steroid dose, μg/day
(mean ± SD)§
320.4 ± 158.8
(n = 17)
360 ± 151.4
(n = 15)
0.48
Rescue medication use (puffs/day)¥ 2.27 ± 1.5
(n = 26)
1.98 ± 2.09
(n = 20)
0.19
§ Daily dose of inhaled steroids in beclomethasone μg equivalents over the past 1-2 wk.
These were calculated on the assumption that beclomethasone 2000 μg = budesonide 1600 μg = fluticasone 1000 μg.
¥ Rescue medication = Inhaled rescue bronchodilator intake (puffs/day) use per day and an average for 2 weeks preceding the study visit.
p-value obtained from Chi-square analysis or Mann-Whitney U test.
Table 3: Results of pulmonary function indices during the study
Parameter Group Week 0 Week 2 Week 4 Week 8 p-value
PEFR Yoga 68.6 ± 18.4 76.5 ± 20.5* 81.5 ± 20.9‡ 85.3 ± 20.7‡ 0.000
Control 57.4 ± 19.7 58.2 ± 22.0 56.9 ± 26.2 56.2 ± 22.0
FEV1 Yoga 70.2 ± 17.4 73.9 ± 19.6 76.1 ± 20.1 77.9 ± 17.2* 0.009
Control 62.5 ± 19.2 63.1 ± 20.5 60.5 ± 21.6 59.9 ± 19.1
FVC Yoga 78.7 ± 13.4 78.0 ± 12.6 79.3 ± 13.0 82.2 ± 10.7 NS
Control 75.0 ± 15.0 74.7 ± 18.3 73.4 ± 18.1 72.5 ± 17.5
FEV1/FVC Yoga 80.4 ± 11.5 82.6 ± 13.3 83.7 ± 13.4 83.1 ± 12.2 0.011
Control 73.7 ± 14.9 74.8 ± 13.9 72.4 ± 15.1 73.3 ± 13.8
FEF25–75% Yoga 38.4 ± 14.6 42.0 ± 19.4 45.0 ± 20.5 45.0 ± 19.7 0.035
Control 34.0 ± 18.3 33.8 ± 17.8 32.4 ± 18.1 31.1 ± 17.1
All values are % of predicted and expressed as mean ± SD.
* p < .05; † p < .01; ‡ p < .001 based on post-hoc pair wise comparisons with 0 wk values.
p-values were obtained from the between groups comparison in the GLM, NS – not significantBMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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itation does not reduce the external validity of the study
because in practice only those subjects opt for a particular
modality of treatment who have faith in its efficacy.
We chose, keeping the subjects' convenience and our
infrastructure in mind, a 2-wk supervised out-patient
intervention at IHC followed by 6 wk of closely moni-
tored intervention at home. The 2-wk training period was
adequate to make the subjects reasonably proficient in
physical postures, breathing exercises, meditation and
relaxation techniques, and to acquaint them with princi-
ples of stress management and a healthy yoga-based life-
style. Leaving the subject to continue with these practices
on his own and apply the principles learnt to everyday sit-
uations for 6 wk was reasonably long to test the feasibility
of the intervention in real life, and to assess how far the
gains achieved in 2 wk of supervised training were sus-
tained during follow-up. Not only could the subjects con-
Table 4: Exercise induced bronchoconstriction during the study
Category Group Week 0 Week 2 Week 4 Week 8 p-value
% fall in FEV1 with exercise challenge Yoga
(n = 29)
15.05 ± 14.0 8.81 ± 12.9 5.65 ± 12.9 5.18 ± 11.8 0.005
Control
(n = 28)
9.13 ± 10.8 9.50 ± 11.1 10.28 ± 10.9 5.81 ± 10.1 NS
ES subjects
(≥ 15% fall in FEV1)
Yoga
(n = 13)
26.71 ± 12.7 13.33 ± 16.1 9.90 ± 14.5 7.95 ± 15.1 0.003
Control
(n = 9)
21.47 ± 6.4 8.83 ± 9.8 18.69* ± 8.2 12.71 ± 9.1 0.015
ER subjects
(<15% fall in FEV1)
Yoga
(n = 16)
5.58 ± 5.1 5.13 ± 8.4 2.20 ± 10.6 2.93 ± 8.0 NS
Control
(n = 19)
3.29 ± 6.6 9.82 ± 11.9 6.31 ± 9.8 2.53 ± 9.0 NS
All values are expressed as mean ± SD. ES – exercise sensitive; ER – exercise resistant.
P-value was based on Friedman test applied on % fall in FEV1 after exercise challenge within each group separately.
* Between groups comparisons were made by Mann-Whitney U test at individual visits, there was significant difference observed at 4 wk between 
groups in exercise-sensitive subjects (p = 0.025).
Table 5: Normalized values of Δ urinary 11β-PGF2α with exercise challenge
Category Group Week 0 Week 2 Week 4 Week 8 p-
valuea
% change in 11β-PGF2α excretion. (All subjects) Yoga
(n = 29)
17.6 ± 18.6 19.7 ± 24.7 14.7 ± 16.5 16.8 ± 19.7 0.49
Control (n = 28) 16.6 ± 21.0 18.6 ± 22.0 16.3 ± 22.3 20.7 ± 23.5 0.84
ES subjects
(mean ± SD)
Yoga
(n = 13)
18.3 ± 22.2 20.4 ± 29.5 13.8 ± 16.8 12.3 ± 16.9 0.63
Control
(n = 9)
15.5 ± 21.2 13.3 ± 18.1 28.5 ± 16.3* 18.9 ± 8.2 0.11
ER subjects
(mean ± SD)
Yoga
(n = 16)
17.1 ± 15.9 19.0 ± 21.0 15.4 ± 16.8 20.4 ± 21.5 0.79
Control
(n = 19)
17.0 ± 21.5 21.1 ± 23.6 10.6 ± 22.8 21.6 ± 28.2 0.08
All values (normalized) are expressed as % change in 11β prostaglandin F2α excretion with exercise challenge (mean ± SD). ES – exercise sensitive; 
ER – exercise resistant subjects.
aP-value was based on Friedman test in each group separately from % change in 11β-PGF2α with exercise.
*p < .05 based on Mann-Whitney U test at 4 wk between two groups.BMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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tinue with the intervention, the gains of the first 2-wk
were improved upon during the 6-wk follow up.
The various interventions administered under the omni-
bus title 'yoga' cover a very wide spectrum. This is inevita-
ble because yoga is not a system of medicine; it is a way of
life, the implications of which go beyond health and dis-
ease[21]. When yoga is employed for prevention or man-
agement of disease, some convenient and highly visible
elements of yoga are used selectively. Our intervention
has used yoga as a tool in mind-body medicine[22]. This
approach now has a strong scientific foundation in psy-
choneuroimmunology, and is particularly relevant to a
Table 6: Asthma quality of life scores during the study
AQOL sub domains Group Week 0 Week 2 Week 4 Week 8 p-value
Symptoms Yoga 3.77 ± 1.3 5.07 ± 1.4‡ 5.38 ± 1.1‡ 5.42 ± 1.2‡ 0.033
Control 3.63 ± 1.4 3.96 ± 1.7 4.42 ± 1.5† 4.70 ± 1.7†
Activity limitation Yoga 3.66 ± 1.1 4.82 ± 1.3‡ 5.21 ± 1.0‡ 5.47 ± 1.1‡ 0.033
Control 3.67 ± 1.2 3.74 ± 1.5 3.90 ± 1.4 4.20 ± 1.5
Emotional function Yoga 3.94 ± 1.5 5.10 ± 1.6† 5.45 ± 1.3‡ 5.71 ± 1.3‡ 0.006
Control 3.60 ± 1.4 4.01 ± 1.6 4.15 ± 1.8 4.32 ± 1.7
Response to environmental stimuli Yoga 3.46 ± 1.5 4.64 ± 1.5‡ 5.0 ± 1.4‡ 5.3 ± 1.6‡ NS
Control 4.04 ± 1.4 3.83 ± 1.5 4.08 ± 1.6 4.40 ± 1.8
Total Quality of Life Yoga 3.72 ± 1.2 4.93 ± 1.3‡ 5.28 ± 1.0‡ 5.46 ± 1.1‡ 0.013
Control 3.64 ± 1.1 3.90 ± 1.5 4.17 ± 1.4* 4.50 ± 1.5†
All values are expressed as mean ± SD.
* p < .05; † p < .01; ‡ p < .001 based on post-hoc pair wise comparisons with 0 wk values.
p-values were obtained from the between groups comparison in the GLM, NS – not significant.
Serum eosinophilic cationic protein in yoga group during the  study Figure 1
Serum eosinophilic cationic protein in yoga group 
during the study. Serum eosinophilic cationic protein in 
yoga group (n = 29) during 8 wk study period. Horizontal 
thick bars indicate median values and box the interquartile 
range (IQR).
Serum eosinophilic cationic protein in control group during  the study Figure 2
Serum eosinophilic cationic protein in control group 
during the study. Serum eosinophilic cationic protein in 
control group (n = 28) during 8 wk study periodBMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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disorder like bronchial asthma which is characterized by
deranged immune function.
The results of the present study allow a few fairly firm con-
clusions. Significant, steady and progressive improvement
in key objective variables such as PEFR and FEV1 only in
the yoga group but not in the control group indicates the
efficacy of yoga. This is further substantiated by the signif-
icantly greater improvement in quality of life in the yoga
group than in the control group.
In yoga group, there was also a significant trend towards
improvement in exercise tolerance assessed by the exer-
cise-induced fall in FEV1, which became more evident in
ES subjects. The effects of yoga on EIB in our study are
similar to those reported by Jain et al. (1991)[5], who
demonstrated a significant increase in exercise tolerance
as indicated by a decrease in exercise-induced bronchial
lability index (BLI) with yoga practice for 40-days in ado-
lescents with mild to severe asthma and in another study
by the same authors in moderate to severe chronic asthma
patients[23].
Since the blood level of ECP is directly related to the sever-
ity of asthma and inversely related to lung functions, we
have used ECP as a peripheral marker in understanding
the disease progress [24,25]. In our present study, no sig-
nificant changes were observed in ECP in either group.
The high variability in ECP levels suggests the need for a
much larger number of subjects for arriving at definitive
conclusions.
Apart from the IgE mediated mast cell activation[26],
mast cells may also be activated independently of high
affinity IgE receptor (FcεRI), by emotional stress and it can
induce asthma exacerbations [27,28]. The possibility is
made more likely because psychological or emotional
stress triggers dura mast cell secretion via release of corti-
cotropin-releasing hormone, CRH[29]. Another study
also indicated that acute psychological stress could lead to
cardiac mast cell degranulation through CRH acting
directly or through neurotensin[30]. Therefore, we specu-
lated that yoga might play a vital role in reducing the mast
cell activation levels by improving the emotional function
of asthmatics thereby reducing the inflammatory condi-
tion and would cause the favourable effects on this out-
come measure.
Another plausible explanation for the role of yoga in
reducing the mast cell degranulation could be based on
the frictional stress from air flowing through narrowed
airways damaging the airway mucosa and thereby perpet-
uating airway inflammation and airway obstruction. At
high air flow rates, high values of the frictional stress
could damage the airway wall, especially during episodes
of cough, and particularly when the mucosa is inflamed
and friable as it is in asthmatic patients[31]. The slow and
gentle breathing in some of the pranayamas (breathing
practices in yoga) may reverse the process[32] by reducing
the frictional stress, and thereby stabilizing the mast cell
degranulation. Olness et al. (1999)[33] also demonstrated
an inhibition of mast cell activation by conditioned relax-
ation techniques such as relaxation-imagery in children
having migraine. In the present study, the urinary concen-
trations of 11β-PGF2α against exercise stimuli in yoga and
control groups did not show any significant trend towards
the inhibition of mast cell activation except a significant
difference observed between groups at 4 wk in ES subjects
(Table 5). Therefore, our study could not examine conclu-
sively the above speculations because of high variability of
11β-PGF2α and a small sample size (yoga, 13; control, 9)
in ES subjects. In addition, the exercise in the present
study was a much less vigorous stimulus for provocation
of airways and activating the mast cells than allergen prov-
ocation in which approximately 200–300% increase is
seen in levels of urinary 11β-PGF2α with an allergen chal-
lenge[34].
The favourable effect of yoga in bronchial asthma
observed by us in some outcome measures is consistent
with similar results reported in several previous studies[3-
5,10]. Most of these, except the study by Jain et al
Frequency of rescue medication use in yoga and control  groups Figure 3
Frequency of rescue medication use in yoga and con-
trol groups. Rescue medication use was calculated as an 
average use of short acting β2-agonists per day (puffs/day) for 
2 wk, hence, there are five time points. There is significant 
overall decline in rescue medication use in both yoga (p < 
.001) and control groups (p < .05). Also significant differ-
ences seen at 2 wk (p < .05) and 4 wk (p < .01) between yoga 
and control groups.BMC Pulmonary Medicine 2009, 9:37 http://www.biomedcentral.com/1471-2466/9/37
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(1991)[5], were also randomized controlled trials. But
lately there have been a few studies which have reported
either negative or very weak effects of yoga[6-9,35]. All
these were also controlled trials, and the study designs are
apparently more rigorous than in the earlier trials. How-
ever, that does not necessarily mean that the positive
results of earlier studies were due to insufficient rigor.
Rather, it seems that in order to meet the exacting
demands of methodology, some of the recent studies have
overlooked some basic features of yoga. Moreover, yoga is
much more than breathing exercises. It is only an inte-
grated practice e.g. that given in the study by Nagarathna
and Nagendra (1985)[10] or in the present study, which
comes closest in an experimental situation to what yoga
really is. In the study by Sabina et al (2005)[9], yoga has
been equated with postures or breath work. The frequency
is only twice a week without any serious monitoring of the
frequency with which the practices are repeated at home
on other days. Moreover, the control is a stretch. If yogic
stretches are also treated like just a stretch, a non-yogic
stretch could be equally good. It is only when the yogic
stretch is performed with a yogic attitude, and preferably,
when it becomes a component in the yogic way and view
of life, that the yogic stretch acquires superiority over a
non-yogic stretch[36]. That is possibly the reason why in
the study by Sabina et al (2005)[9], both groups improved
but the difference between the groups was not significant.
In the most recent studies[8,9], the scientific rigor has
been improved upon by giving to the control group an
intervention similar to that given to the yoga group, and
the trials have been masked. Masking in a study which
involves highly visible physical practices is meaningless.
Further, if the interventions in the two groups are very
similar, the outcomes in the two groups cannot be very
different. The mere fact that in one group the techniques
have been selected from a yogic text and in the other from
a text on physiotherapy or modern psychology will not
affect the outcome. Further, the comprehensive approach
to yoga has been avoided probably to keep the interven-
tion well-defined. But in the process of testing a holistic
treatment using a design which is ideal for testing a drug,
the holistic treatment should not be reduced to one of its
components. For the sake of fitting our design into a rigid
framework, we should not end up evaluating a modality
of treatment which is different from the one we have set
out to examine. That answers also one of the commonest
criticisms leveraged at studies like the present one i.e. the
study does not allow us to determine the proportionate
contribution of each component of the intervention. To
view a holistic treatment as a combination of components
is convenient but inappropriate. The efficacy observed is
that of the whole intervention, and may be greater than
the sum of the efficacy of its components.
The present study is the first one to attempt an investiga-
tion into the mechanism by which yoga helps bronchial
asthma. Although it has not succeeded in throwing much
light in that direction, there are several other subtle rea-
sons why this study and many more similar studies in the
future would be justified. Although there are several stud-
ies available on the efficacy of yoga in bronchial asthma
and several other diseases, studies have to reach a critical
mass before they can influence practice. Further, in case of
yoga, very few of the studies are randomized controlled
trials[1]. Because of the dilution of a few RCTs by several
less rigorous trials, and also because of widespread scepti-
cism with which disciplines like yoga are approached by
practitioners of conventional medicine, the impact of the
RCTs is inadequate. Further, it would help to integrate
mind-body approaches like yoga into the practice of sci-
entific medicine if the trials not only show that these
approaches work, but also how they work in terms of
measurable basic mechanisms.
Conclusion
The present RCT has shown that adding a comprehensive
yoga-based mind-body intervention to the conventional
treatment improves several measures of pulmonary func-
tion in subjects having mild to moderate bronchial
asthma. There is a significant trend suggesting a decrease
in exercise-induced bronchoconstriction in the yoga
group, particularly in the exercise-sensitive subjects. Yoga
and control groups did not show a clear trend towards the
inhibition of mast cell activation except for a significant
difference observed between groups at 4 wk in exercise-
sensitive subjects. Once again, in view of the high variabil-
ity in response, a much larger number of exercise-sensitive
subjects are required for definitive conclusions. Yoga
improves the quality of life and reduces rescue medication
use in bronchial asthma, and achieves the reduction ear-
lier than conventional treatment alone. The trial supports
the use of yoga in the management of bronchial asthma.
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